search

Tenaya Therapeutics Inc (TNYA)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Tenaya Therapeutics CEO Ali Faraz Receives 122,000 Shares and 732,500 Derivative Securities at No Cost (NASDAQ: TNYA)
Sep 15, 2026

Tenaya Therapeutics CEO Ali Faraz Receives 122,000 Shares and 732,500 Derivative Securities at No Cost (NASDAQ: TNYA)

Tenaya Therapeutics CEO Ali Faraz received 122,000 shares and 732,500 derivative securities at no cost on September 10. The share award increased his total holdings to 539,782 shares, representing 22.6% of his post-award total. The derivative securities constitute 100% of his derivative holdings after the transaction, which was classified under code A, indicating a grant.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish
Tenaya Therapeutics Grants 49,000 Shares to CMO Tingley Whittemore (NASDAQ: TNYA)
Sep 14, 2026

Tenaya Therapeutics Grants 49,000 Shares to CMO Tingley Whittemore (NASDAQ: TNYA)

Tenaya Therapeutics (NASDAQ: TNYA) awarded 49,000 shares at no cost to its Chief Medical Officer, Tingley Whittemore, on September 10, 2026. This transaction increased Whittemore's total shareholding to 263,073 shares and included a separate grant of 293,000 derivative securities. The awards provide transparency into executive compensation and holdings, with the share grant representing approximately 18.6% of Whittemore's post-award total shares.
Company relevance
100.00%
Company sentiment
Neutral
Overall sentiment
Neutral